Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases

Gut. 2006 Jul;55(7):1058-9. doi: 10.1136/gut.2005.090571.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms / blood
  • Colorectal Neoplasms / pathology*
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Endostatins / blood
  • Humans
  • Lactones / therapeutic use*
  • Liver Neoplasms / blood
  • Liver Neoplasms / blood supply*
  • Liver Neoplasms / secondary*
  • Neovascularization, Pathologic / drug therapy*
  • Sulfones / therapeutic use*
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Cyclooxygenase 2 Inhibitors
  • Endostatins
  • Lactones
  • Sulfones
  • Vascular Endothelial Growth Factor A
  • rofecoxib